Please select your page
  • Slide
  • Slide
  • Slide

Press release

CERENIS Therapeutics acquires LYPRO Biosciences expanding its HDL strategy
into immuno-oncology and chemotherapeutic drug delivery

8 novembre 2017,

• Combining LYPRO Biosciences’ NanoDisk® technology with CERENIS’ HDL solution to build the first HDL nanoparticle delivery platform to be initially dedicated to the oncology market

• Using its existing technologies with LYPRO’s NanoDisk® discoidal HDL, CERENIS is positioned to utilize HDL related particles to selectively target a wide variety of tissues

• Phase I study, evaluating the safety of the platform technology in active drug delivery to cancer tissues, to be launched by the end of 2019

• New strategic markets and value-creation prospects: Immuno-oncology is one of the most promising cancer treatment technology in a market valued at $100 billion by 2020

 

 Click here to download the slideshow of the presentation

Full Press Release

Events Date
2016 Full Year Results February 17, 2017
Cash position and revenue for Q1 2017 April 20, 2017
Annual General Meeting June 9, 2017
Cash position and revenue for Q2 2017 July 20, 2017
2017 Half Year Results September 12, 2017
Cash position and revenue for Q3 2017 October 26, 2017
Cash position and revenue for Q4 2017 January 25, 2018

Contact

Cerenis Therapeutics Holding SA
265 rue de la Découverte - Bât. A
31670 Labège, France
Tél. : +33 (0) 5 62 24 97 06
Fax : +33 (0) 5 62 19 04 17

Email: info@cerenis.com

Cerenis Therapeutics Inc
PO Box 861
Lakeland, MI 48143
USA